Patents by Inventor David Gilot

David Gilot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10287633
    Abstract: The present invention relates to methods and reagents for the treatment of melanoma and/or of metastatic melanoma that directly or indirectly target TYRP1 RNA transcript. The invention also relates to methods for predicting if a melanoma patient will be therapeutically responsive to such methods of treatment and reagents, and to methods for assessing the effectiveness of such methods of treatment and reagents. The invention further relates to a combination of biological markers that allows the prediction of melanoma patients' survival irrespective of the treatment administered.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: May 14, 2019
    Assignees: UNIVERSITE DE RENNES 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER UNIVERSITAIRE PONTCHAILLOU
    Inventors: David Gilot, Marie-Dominique Galibert, Ghanem Ghanem, Fabrice Journe
  • Publication number: 20160265063
    Abstract: The present invention relates to methods and reagents for the treatment of melanoma and/or of metastatic melanoma that directly or indirectly target TYRP1 RNA transcript. The invention also relates to methods for predicting if a melanoma patient will be therapeutically responsive to such methods of treatment and reagents, and to methods for assessing the effectiveness of such methods of treatment and reagents. The invention further relates to a combination of biological markers that allows the prediction of melanoma patients' survival irrespective of the treatment administered.
    Type: Application
    Filed: November 6, 2014
    Publication date: September 15, 2016
    Inventors: David Gilot, Marie-Dominique Galibert, Ghanem Ghanem, Fabrice Journe